Publication:
Cognitive and metabolic outcomes of vildagliptin addition to the therapy in patients with type 2 diabetes mellitus: 26 week follow-up study

Thumbnail Image

Organizational Units

Program

Authors

Bulut, Esra Ates
Alak, Zehra Yagmur Sahin
Dokuzlar, Ozge
Kocyigit, Suleyman Emre
SOYSAL, PINAR
Smith, Lee
IŞIK, AHMET TURAN

Advisor

Language

Publisher

Journal Title

Journal ISSN

Volume Title

Abstract

Aims: Type 2 Diabetes Mellitus(DM) is a well-known risk factor for cognitive impairment. Recent evidences suggest that Dipeptidyl peptidase-4(DPP-4) inhibitors might have neuroprotective effects. Therefore, this study aimed to investigate vildagliptin, a DPP-4 inhibitor, effects on cognitive function in older patients with DM.

Description

Source:

Keywords:

Keywords

Citation

Bulut E. A. , Alak Z. Y. S. , Dokuzlar O., Kocyigit S. E. , SOYSAL P., Smith L., IŞIK A. T. , -Cognitive and metabolic outcomes of vildagliptin addition to the therapy in patients with type 2 diabetes mellitus: 26 week follow-up study-, ARCHIVES OF GERONTOLOGY AND GERIATRICS, cilt.88, 2020

Endorsement

Review

Supplemented By

Referenced By

0

Views

8

Downloads

View PlumX Details


Sustainable Development Goals

Thumbnail Image
Goal